Research programme: enzyme inhibitors - Lixte Biotechnology Holdings

Drug Profile

Research programme: enzyme inhibitors - Lixte Biotechnology Holdings

Alternative Names: Cancer therapeutics - Lixte; LB-1.2; LB-102; LB-2.1; LB-200 series - Lixte; LB-201; LB-205; LB-300 series - Lixte; LB-400 series - Lixte; Neurological therapeutics - Lixte

Latest Information Update: 14 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lixte Biotechnology Holdings
  • Developer Lixte Biotechnology Holdings; National Institute of Neurological Disorders and Stroke; National Institutes of Health (USA)
  • Class Antineoplastics; Cycloheptanes; Neuroprotectants; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Phosphoprotein phosphatase inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Amyotrophic lateral sclerosis; Gaucher's disease; Mycoses; Neurological disorders

Most Recent Events

  • 09 Feb 2018 LB 102 is still in preclinical studies for Cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gaucher's-disease in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top